103 related articles for article (PubMed ID: 30707896)
1. High levels of RAI3 expression is linked to shortened survival in esophageal cancer patients.
El Gammal AT; Melling N; Reeh M; Gebauer F; Mann O; Perez D; Bockhorn M; Bachmann K; Izbicki JR; Grupp K
Exp Mol Pathol; 2019 Apr; 107():51-56. PubMed ID: 30707896
[TBL] [Abstract][Full Text] [Related]
2. FOXO1 overexpression and loss of pSerine256-FOXO1 expression predicts clinical outcome in esophageal adenocarcinomas.
Grupp K; Uzunoglu FG; Melling N; Hofmann B; El Gammal AT; Grotelüschen R; Heumann A; Bellon E; Reeh M; Wolters-Eisfeld G; Ghabdan T; Nentwich M; Bachmann K; Bockhorn M; Bogoevski D; Izbicki JR; Kutup A
Sci Rep; 2018 Nov; 8(1):17370. PubMed ID: 30478420
[TBL] [Abstract][Full Text] [Related]
3. Increased lysophosphatidylcholine acyltransferase 1 expression is unrelated to prognosis of esophageal cancer patients.
Bellon E; Grupp K; Ghadban T; Tachezy M; Bachmann K; Izbicki JR; Simon R; Sauter G; Hube-Magg C; Melling N
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2879-2884. PubMed ID: 34148155
[TBL] [Abstract][Full Text] [Related]
4. Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome.
Grupp K; Hofmann B; Kutup A; Bachmann K; Bogoevski D; Melling N; Uzunoglu FG; El Gammal AT; Koop C; Simon R; Steurer S; Krech T; Burdak-Rothkamm S; Jacobsen F; Sauter G; Izbicki J; Wilczak W
BMC Cancer; 2018 Nov; 18(1):1106. PubMed ID: 30419865
[TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of Sec61α in esophageal cancers.
Bachmann K; Bockhorn M; Mann O; Gebauer F; Blessmann M; Izbicki JR; Grupp K
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2039-2044. PubMed ID: 31197453
[TBL] [Abstract][Full Text] [Related]
6. RAI3 is overexpressed in gastric adenocarcinoma but unrelated to prognosis.
Melling N; Bachmann K; Bockhorn M; Mann O; Izbicki JR; Grupp K
Int J Clin Exp Pathol; 2019; 12(2):606-612. PubMed ID: 31933866
[TBL] [Abstract][Full Text] [Related]
7. RAI3 expression is not associated with clinical outcomes of patients with non-small cell lung cancer.
Melling N; Reeh M; Ghadban T; Tachezy M; Hajek A; Izbicki JR; Grupp K
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6549-6555. PubMed ID: 36781501
[TBL] [Abstract][Full Text] [Related]
8. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.
Salem ME; Puccini A; Xiu J; Raghavan D; Lenz HJ; Korn WM; Shields AF; Philip PA; Marshall JL; Goldberg RM
Oncologist; 2018 Nov; 23(11):1319-1327. PubMed ID: 29866946
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.
Wang K; Johnson A; Ali SM; Klempner SJ; Bekaii-Saab T; Vacirca JL; Khaira D; Yelensky R; Chmielecki J; Elvin JA; Lipson D; Miller VA; Stephens PJ; Ross JS
Oncologist; 2015 Oct; 20(10):1132-9. PubMed ID: 26336083
[TBL] [Abstract][Full Text] [Related]
10. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.
Dunne MR; Michielsen AJ; O'Sullivan KE; Cathcart MC; Feighery R; Doyle B; Watson JA; O'Farrell NJ; Ravi N; Kay E; Reynolds JV; Ryan EJ; O'Sullivan J
Cancer Immunol Immunother; 2017 Jul; 66(7):841-850. PubMed ID: 28315927
[TBL] [Abstract][Full Text] [Related]
11. High TSTA3 Expression as a Candidate Biomarker for Poor Prognosis of Patients With ESCC.
Yang J; Kong P; Yang J; Jia Z; Hu X; Wang Z; Cui H; Bi Y; Qian Y; Li H; Wang F; Yang B; Yan T; Ma Y; Zhang L; Cheng C; Song B; Li Y; Xu E; Liu H; Gao W; Wang J; Liu Y; Zhai Y; Chang L; Wang Y; Zhang Y; Shi R; Liu J; Wang Q; Cheng X; Cui Y
Technol Cancer Res Treat; 2018 Jan; 17():1533033818781405. PubMed ID: 29950151
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of insulin-like growth factor II mRNA-binding protein 3 (IMP3) has negative prognostic impact on early invasive (pT1) adenocarcinoma of the esophagus.
Plum PS; Ulase D; Bollschweiler E; Chon SH; Berlth F; Zander T; Alakus H; Hölscher AH; Bruns CJ; Schallenberg S; Quaas A; Loeser H
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1731-1739. PubMed ID: 29974234
[TBL] [Abstract][Full Text] [Related]
13. miR-486-5p expression pattern in esophageal squamous cell carcinoma, gastric cancer and its prognostic value.
Ren C; Chen H; Han C; Fu D; Zhou L; Jin G; Wang F; Wang D; Chen Y; Ma L; Zheng X; Han D
Oncotarget; 2016 Mar; 7(13):15840-53. PubMed ID: 26895105
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological significance of wnt/β-catenin signaling pathway in esophageal squamous cell carcinoma.
Deng F; Zhou K; Cui W; Liu D; Ma Y
Int J Clin Exp Pathol; 2015; 8(3):3045-53. PubMed ID: 26045816
[TBL] [Abstract][Full Text] [Related]
15. Tenascin-C, a Prognostic Determinant of Esophageal Squamous Cell Carcinoma.
Yang ZT; Yeo SY; Yin YX; Lin ZH; Lee HM; Xuan YH; Cui Y; Kim SH
PLoS One; 2016; 11(1):e0145807. PubMed ID: 26731558
[TBL] [Abstract][Full Text] [Related]
16. The zinc-finger transcription factor SALL4 is frequently expressed in human cancers: association with clinical outcome in squamous cell carcinoma but not in adenocarcinoma of the esophagus.
Kilic E; Tennstedt P; Högner A; Lebok P; Sauter G; Bokemeyer C; Izbicki JR; Wilczak W
Virchows Arch; 2016 Apr; 468(4):483-92. PubMed ID: 26818834
[TBL] [Abstract][Full Text] [Related]
17. Loss of PAR-3 protein expression is associated with invasion, lymph node metastasis, and poor survival in esophageal squamous cell carcinoma.
Kitaichi T; Yasui K; Gen Y; Dohi O; Iwai N; Tomie A; Yamada N; Terasaki K; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Sumida Y; Mitsuyoshi H; Naito Y; Zen Y; Itoh Y
Hum Pathol; 2017 Apr; 62():134-140. PubMed ID: 28188749
[TBL] [Abstract][Full Text] [Related]
18. Association of p53 expression with prognosis in patients with esophageal squamous cell carcinoma.
Yao W; Qin X; Qi B; Lu J; Guo L; Liu F; Liu S; Zhao B
Int J Clin Exp Pathol; 2014; 7(10):7158-63. PubMed ID: 25400812
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D receptor is highly expressed in precancerous lesions and esophageal adenocarcinoma with significant sex difference.
Zhou Z; Xia Y; Bandla S; Zakharov V; Wu S; Peters J; Godfrey TE; Sun J
Hum Pathol; 2014 Aug; 45(8):1744-51. PubMed ID: 24951052
[TBL] [Abstract][Full Text] [Related]
20. Integrin α5 promotes tumor progression and is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma.
Xie JJ; Guo JC; Wu ZY; Xu XE; Wu JY; Chen B; Ran LQ; Liao LD; Li EM; Xu LY
Hum Pathol; 2016 Feb; 48():69-75. PubMed ID: 26772401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
